With the fall ACS national meeting right around the corner, the time has come to put your poster presentation together. While the abstract was submitted months ago, you were waiting to create the ...
Affimed N.V., a clinical-stage immuno-oncology company, announced that an abstract on its phase 2 LuminICE-203 study involving the innate cell engager acimtamig in combination with AlloNK has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results